北京市天元律师事务所 关于青岛百洋医药股份有限公司 2025 年第三次临时股东大会的 法律意见 京天股字（2025）第 557 号 致：青岛百洋医药股份有限公司 青岛百洋医药股份有限公司（以下简称"公司"）2025 年第三次临时股东大会 （以下简称"本次股东大会"）采取现场投票与网络投票相结合的方式召开，其中 现场会议于 2025 年 9 月 17 日 14：00 在山东省青岛市市北区桐柏路 88 号 1 号楼 青岛百洋医药股份有限公司会议室召开。北京市天元律师事务所（以下简称"本 所"）接受公司聘任，指派本所律师出席本次股东大会并进行见证，并根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）、《上市公司股东会规则（2025 修订）》（以下简称"《股东会规则》"） 以及《青岛百洋医药股份有限公司章程》（以下简称"《公司章程》"）等有关规定， 就本次股东大会的召集、召开程序、出席现场会议人员的资格、召集人资格、会 议表决程序及表决结果等事项出具本法律意见。 为出具本法律意见，本所律师审查了《青岛百洋医药股份有限公司第三届董 事会第三十三次会议决议公告》 ...

证券代码：301015 证券简称：百洋医药 债券代码：123194 债券简称：百洋转债 东兴证券股份有限公司关于 青岛百洋医药股份有限公司 向不特定对象发行可转换公司债券 2025 年度第二次临时受托管理事务报告 （债券受托管理人） 重要声明 本报告依据《公司债券发行与交易管理办法》（以下简称"《管理办法》"）《公 司债券受托管理人执业行为准则》《青岛百洋医药股份有限公司（作为发行人） 与东兴证券股份有限公司（作为受托管理人）关于向不特定对象发行可转换公司 债券之受托管理协议》（以下简称"《受托管理协议》"）《青岛百洋医药股份有限 公司创业板向不特定对象发行可转换公司债券募集说明书》（以下简称"《募集说 明书》"）等相关公开信息披露文件、第三方中介机构出具的专业意见等，由本次 债券受托管理人东兴证券股份有限公司（以下简称"东兴证券"）编制。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为东兴证券所作的承诺 或声明。在任何情况下，投资者依据本报告所进行的任何作为或不作为，东兴证 券不承担任何责任。 1 东兴证券股份有限公司作为青岛百洋医药 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-080 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会未出现否决议案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.召开时间： （1）现场会议召开时间：2025年9月17日（星期三）14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为： 2025年9月17日9:15—9:25，9:30—11:30和13:00—15:00；通过深圳证券交易所互 联网投票系统投票的时间为：2025年9月17日9:15—15:00。 2.召开地点：山东省青岛市市北区桐柏路88号1号楼青岛百洋医药股份有限 公司会议室 3.召开方式：本次股东大会采用现场表决与网络投票相结合的方式召开 4.召集人：董事会 5.主持人：董事长付钢 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-081 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 董事会 2025 年 9 月 17 日 附件：第四届董事会职工代表董事简历 关于选举第四届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 张圆女士将与公司 2025 年第三次临时股东大会选举的董事共同组成公司第 四届董事会，任期自股东大会选举非职工代表董事之日起三年。 本次换届选举完成后，公司第四届董事会中兼任高级管理人员职务的董事以 及由职工代表担任的董事总计不超过公司董事总数的二分之一，符合相关法律法 规的规定。 特此公告。 青岛百洋医药股份有限公司 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》等法律法规、规范性文件及《公司章程》 的有关规定，青岛百洋医药股份有限公司（以下简称"公司"）于 2025 年 9 月 17 日召开职工代表大会，经与会职工代表认真审议和 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-083 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 关于董事会完成换届选举及 聘任高级管理人员、证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、第四届董事会及专门委员会组成情况 （一）董事会组成情况 第四届董事会由 9 名董事组成，其中非独立董事 6 名（其中 1 名为职工代表 董事），独立董事 3 名（其中 1 名为会计专业人士）。 非独立董事：付钢先生（董事长）、宋青女士、朱晓卫先生、陈海深先生、 李震先生、张圆女士（职工代表董事）； 独立董事：郝先经先生（会计专业人士）、陆银娣女士、HO KWOK WAI ANDY （何国伟）先生。 第四届董事会任期自股东大会审议通过之日起三年。第四届董事会成员中兼 任高级管理人员职务的董事以及由职工代表担任的董事总计不超过董事总数的 二分之一，独立董事不低于董事总数的三分之一，符合相关法律法规的规定。独 立董事的任职资格已经深圳证券交易 ...

Core Viewpoint - Qingdao Baiyang Pharmaceutical Co., Ltd. has signed a strategic cooperation agreement with Tianjin Jikun Pharmaceutical Technology Co., Ltd., planning to invest in a 24% stake in Jikun Pharmaceutical, securing rights to an innovative drug for treating pulmonary fibrosis and gaining priority purchase rights for all global compound rights of Jikun's products [1][2]. Group 1 - The strategic investment will allow Baiyang Pharmaceutical to lock in all rights related to the innovative drug project JK1033, which targets idiopathic pulmonary fibrosis (IPF) through a novel mechanism [1]. - JK1033 is a small molecule compound that can inhibit multiple fibrosis-related target cells/pathways, achieving anti-fibrotic, anti-inflammatory, and anti-epithelial injury effects [1]. - The project has initiated Phase I clinical trials in China and has completed Pre-IND communication with the FDA in the United States, with plans to submit an IND application [1]. Group 2 - Upon achieving certain progress in the JK1033 project, Baiyang Pharmaceutical will have the right to acquire the project rights at a mutually agreed reasonable price, which will enhance its product pipeline in the innovative drug sector [2]. - This collaboration will strengthen Baiyang's product portfolio in the treatment of liver and pulmonary fibrosis, consolidating its position in the fibrosis disease treatment field [2].

Core Viewpoint - Baiyang Pharmaceutical Group signed a strategic cooperation agreement with the Beijing Medical and Health Technology Promotion Center to enhance collaboration in key areas such as scientific research innovation and achievement transformation, aiming to accelerate the implementation of innovative results [1] Group 1 - The China International Fair for Trade in Services was held from September 10 to 14 at the Shougang Park in Beijing [1] - The signing event focused on health and sanitation services, highlighting the importance of strategic partnerships in the healthcare sector [1] - The collaboration aims to promote deeper cooperation in research and innovation, facilitating the rapid application of original innovative achievements [1]

Group 1 - Baiyang Pharmaceutical plans to strategically invest in Jikun Pharmaceutical by acquiring a 24% stake, securing rights to the innovative drug for pulmonary fibrosis, JK1033, and gaining priority purchase rights for all global compound rights of Jikun Pharmaceutical's products [1] - Qianjin Pharmaceutical received approval from the China Securities Regulatory Commission to issue shares and purchase stakes in Hunan Qianjin Xiangjiang Pharmaceutical (28.92%) and Hunan Qianjin Xieli (68%), enhancing its collaboration in the western medicine sector and supporting its "one main, two auxiliary" strategy [2] - BGI Genomics' major shareholder, Shenzhen BGI Genomics Technology Co., plans to transfer 4% of its shares (16.73 million shares) through a pricing inquiry to meet funding needs for cutting-edge technology incubation in cell and spatiotemporal genomics [3] Group 2 - Suoyuan Biotech's key ENLIGHTEN trial results were published in the prestigious journal JAMA Psychiatry, showing significant efficacy of DB104 (Liafensine) in treatment-resistant depression patients with the ANK3 biomarker, marking a breakthrough in precision medicine for mental health [4] - Betta Pharmaceuticals intends to list on the Hong Kong Stock Exchange, reporting a revenue of 1.731 billion yuan in the first half of 2025, a 15.37% increase, but a net profit decline of 37.53% to 140 million yuan, indicating challenges despite growth in revenue [5]

Core Viewpoint - Qingdao Baiyang Pharmaceutical Co., Ltd. has signed a strategic cooperation agreement with Tianjin Jikun Pharmaceutical Technology Co., Ltd., planning to invest in a 24% stake in Jikun Pharmaceutical, securing rights to its innovative drug for pulmonary fibrosis and priority purchase rights for all global compound rights [1][2]. Group 1: Company Overview - Baiyang Pharmaceutical focuses on the commercialization of medical innovations, emphasizing product development, manufacturing, and commercialization [2]. - The company employs a dual-driven model of "investment incubation + commercialization" to concentrate on First-in-Class drugs and original innovative achievements [2]. Group 2: Jikun Pharmaceutical's Profile - Jikun Pharmaceutical specializes in the research and development of innovative drugs for organ fibrosis, inflammatory immune diseases, and tumors, with a complete R&D system from target discovery to clinical development [1]. - The company has established a robust drug screening and evaluation platform for anti-fibrosis, anti-inflammatory, and immune regulation, with seven I-class new drug pipelines in progress [1]. Group 3: Product Development - Jikun Pharmaceutical's core product, JK1033, is a small molecule compound designed to treat idiopathic pulmonary fibrosis (IPF) through a novel mechanism, effectively inhibiting disease progression [1]. - JK1033 is currently in Phase I clinical trials in China and has completed Pre-IND communication with the FDA in the United States, with plans to submit an IND application [1]. Group 4: Strategic Implications - Upon achieving certain milestones with the JK1033 project, Baiyang Pharmaceutical has the right to acquire project rights at a mutually agreed price, potentially enhancing its product pipeline in the innovative drug sector [2]. - This acquisition could strengthen Baiyang Pharmaceutical's product portfolio in both liver and pulmonary fibrosis treatment areas, providing comprehensive solutions for healthcare providers and patients [2].

Core Viewpoint - Baiyang Pharmaceutical has signed a strategic cooperation agreement with Tianjin Jikun Pharmaceutical Technology Co., Ltd., planning to invest in a 24% stake in Jikun Pharmaceutical, securing rights to innovative drugs for treating pulmonary fibrosis and gaining priority purchasing rights for global compound rights of all Jikun Pharmaceutical products [1][2]. Group 1 - Baiyang Pharmaceutical focuses on the commercialization of medical innovations, developing products across four major categories: OTC and health products, prescription drugs, severe disease drugs, and high-end medical devices [2]. - The company has established a multi-brand matrix and created several leading brands in various categories, driven by a dual strategy of "investment incubation + commercialization" [2]. - The partnership with Jikun Pharmaceutical will enhance Baiyang's profitability and market competitiveness by leveraging Jikun's cutting-edge research capabilities alongside Baiyang's established commercialization platform [2]. Group 2 - Jikun Pharmaceutical specializes in innovative drug research for organ fibrosis, inflammatory immune diseases, and tumors, with a complete R&D system from target discovery to clinical development [1]. - The company has developed a mature drug screening and evaluation platform for anti-fibrosis drugs and has established seven I-class new drug pipelines aimed at global markets [1]. - Jikun Pharmaceutical covers over ten organ fibrosis research models, indicating a broad scope of research in the field [1].